{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-24-000089","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.715344+00:00","generated_at":"2026-05-31T13:50:20.024127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aurinia Q2 net product revenue $55M (+34% YoY); net income $0.7M, cash flow positive","bullets":["Net product revenue $55.0M, up 34% YoY; total net revenue $57.2M (+38% YoY).","Net income $0.7M vs loss of $11.5M in Q2 2023; generated $15.8M free cash flow.","Narrows 2024 net product revenue guidance to $210-220M from $200-220M.","2,336 patients on LUPKYNIS (+22% YoY); AUR200 Phase 1 SAD starts Q3 2024.","Cash $330.7M; repurchased 3.4M shares for $18.6M YTD."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-24-000089","json":"https://secwatch.observer/filing/0001600620-24-000089.json","markdown":"https://secwatch.observer/filing/0001600620-24-000089.md","text":"https://secwatch.observer/filing/0001600620-24-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000089/0001600620-24-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000089/auph-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:50:20.024127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}